65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 482 薬物数 : 661 - (DrugBank : 119) / 標的遺伝子数 : 90 - 標的パスウェイ数 : 211

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05104723
(ClinicalTrials.gov)
March 24, 20222/11/2021Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsA Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsChronic Granulomatous Disease;Inflammatory Gastrointestinal Disease;Inflammatory Skin Disease;Inflammatory Lung DiseaseDrug: XELJANZ (tofacitinib)National Institute of Allergy and Infectious Diseases (NIAID)NULLEnrolling by invitation18 YearsN/AAll20Phase 1/Phase 2United States